SCT520FF
Asset
Inhibits VEGF-mediated angiogenesis in the retina.
- Stage
- Phase 1
- Modality
- Antibody
- Target
- Not known
- 1
- Indication
- 1
- Trial
- 1
- Developer
Trial NCT06672536 is still running. Trial NCT06672536 updated in its registry on Sep 4, 2025. clinicaltrials.gov
Indications
1NAMD
Phase 1, Recruiting, NCT06672536, clinicaltrials.gov, Oct 31, 2026
In the full profile
- Owner and partners1
- Trials1
- Competitors1
Every asset’s record: target, stage, trials and the evidence behind it.